Adage Capital Management
Adage Capital is a Boston-based hedge fund founded by Phillip Gross which held nearly $24 billion in securities at the end of the quarter ended September 30, 2010.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
The firm focuses on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation.
View Older Stories View More Recent Stories
-
Form SCHEDULE 13G/A Praxis Precision Medicin Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Zeo Energy Corp. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Inozyme Pharma, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Aligos Therapeutics, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: Adage Capital Management, L.P.
-
BBOT begins trading on Nasdaq after $382M SPAC merger completion
-
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances with a Potential to Realize the Full Promise of KRAS and PI3K Inhibition
-
Equillium secures up to $50 million to advance inflammatory drug EQ504
-
Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic
-
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-
Shattuck Labs raises up to $103 million in oversubscribed private placement
-
Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million
-
Everest Medicines invests $30.9 million in I-MAB, raising stake to 16.1%
-
Everest Medicines Expands Strategic Investment in I-MAB
-
I-Mab prices $65 million offering of American depositary shares
-
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares
-
UNITE 2025 Summit Spotlights HBCU Leaders and Institutions Advancing Educational Excellence
-
Form SCHEDULE 13D/A GLYCOMIMETICS INC Filed by: Adage Capital Management, L.P.
-
Medincell Publishes its Consolidated Annual Financial Results
-
Immunic, Inc. Announces Closing of Oversubscribed $65 Million Underwritten Public Offering
-
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
-
Form 13F-HR ADAGE CAPITAL PARTNERS For: Mar 31
-
Form 13F-NT Adage Capital Management For: Mar 31
-
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Seadrill Ltd Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A ProQR Therapeutics N.V. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Praxis Precision Medicin Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A SOLENO THERAPEUTICS INC Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Wave Life Sciences Ltd. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Solid Biosciences Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Amylyx Pharmaceuticals, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Ensysce Biosciences, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Cidara Therapeutics, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Traws Pharma, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Centessa Pharmaceuticals Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Protara Therapeutics, Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Aeva Technologies, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A UroGen Pharma Ltd. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Mereo BioPharma Group Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A Lexeo Therapeutics, Inc. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G/A ABEONA THERAPEUTICS INC. Filed by: Adage Capital Management, L.P.
-
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approv
-
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
-
Medincell Announces Successful c.€43 Million Global Offering
-
Solid Biosciences (SLDB) Prices 35.74M Share Offering at $4.03/sh
-
Solid Biosciences Announces Pricing of Underwritten Offering
-
Form 13F-HR ADAGE CAPITAL PARTNERS For: Dec 31
-
Form 13F-NT Adage Capital Management For: Dec 31
-
Form SCHEDULE 13G ProQR Therapeutics N.V. Filed by: Adage Capital Management, L.P.
-
Form SCHEDULE 13G Monopar Therapeutics Filed by: Adage Capital Management, L.P.
